NCT02209727View on ClinicalTrials.gov

Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

June 30, 2002

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

131I-Sibrotuzumab

50 mg Sibrotuzumab conjugated with 131I

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02209727 - Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter